Germany proposes to scrap free pricing
This article was originally published in Scrip
Executive Summary
New legislative proposals set out by German federal health minister Philip Rösler have the potential to revolutionise pricing and reimbursement in the pharmaceutical sector. Whilst being hailed by the statutory health insurance funds as long-overdue measures aimed at curbing the spiralling medicines budget, they have been heavily criticised by the research-based pharmaceutical industry.